Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
February 25, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
August 20, 2015 17:16 ET
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis
August 17, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 06, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
PROCYSBI® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter
Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments...
Raptor Pharmaceutical Announces Management Changes
July 15, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and...
Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial)
June 24, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...
Raptor Pharmaceutical Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 07, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
Reports PROCYSBI® Sales of $20.5 Million in First Quarter
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 p.m. PT
NOVATO, Calif., May 7, 2015 (GLOBE NEWSWIRE) --...
Raptor Pharmaceutical to Observe International Rare Disease Day Through Global Awareness Programs
February 23, 2015 08:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Day on February 28, 2015 with a series of initiatives and events...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Thursday, February 26, 2015 at 4:30 p.m. ET
February 17, 2015 08:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2014 financial results on...